Strongbridge Biopharma plc (SBBP) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access SBBP quarterly Cash Flow →
Changes in quarterly cash flow trends offer perspective on how Strongbridge Biopharma plc funds operations, investments, and shareholder returns.
Annual Report, GAAP in USD millions
ITEM
(Dec 31 2020)
12 Months
(Dec 31 2019) (Dec 31 2018) (Dec 31 2017) (Dec 31 2016)
Operating Activities
Income-45.08
Depreciation & amortization0.09
Amortization of Other Assets0.71
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-1.07
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation7.38
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants0.81
Deferred Income Tax Expense Benefit Cash Flow Impact-
Accretion Of Discounts On Marketable Securities-0.05
Income taxes3.90
Gain (Loss) on Disposition of Stock in Subsidiary0.00
Increase (Decrease) in Accounts Receivable0.51
Increase (Decrease) in Accounts Payable-1.85
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities-6.03
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.23
Other Working Capital-0.07
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-38.13
Investing Activities
Capital Expenditures0.01
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Available-for-sale Securities21.12
Payments to Acquire Available-for-sale Securities, Debt0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses and Interest in Affiliates0.00
Interest in Subsidiaries and Affiliates0.00
Proceeds from Divestiture of Businesses and Interests in Affiliates0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities21.11
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings19.33
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock28.60
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.41
Other net-0.41
Proceeds From Issuance Of Common Stock And Warrants Cash Flow Impact-
Proceeds From Issuance Of Common Stock At Market Offering-
Proceeds From Issuance Of Common Stock To Counterparty-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities47.51
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-38.12
Total Cash Flow30.49
4 historic quarters locked

Sign in to unlock the full Strongbridge Biopharma plc cash flow history.

About SBBP Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K
  • Filed with the SEC: n/a

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document





                    
Get the full CSIMarket dataset: Subscribe API License